EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan

Chung,Ching‑Hu

doi:10.3892/ol.2019.10942

EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan

Authors:
- Ching‑Hu Chung
View Affiliations

Affiliations: Department of Medicine and Institute of Long‑Term Care, Mackay Medical College, New Taipei 252, Taiwan, R.O.C.
Published online on: September 30, 2019 https://doi.org/10.3892/ol.2019.10942
Pages: 6090-6100
Copyright: © Chung . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant cancer is the top cause of mortality in Taiwan. In particular, the mortality rate of with lung cancer reached 39.2/100,000 in 2017. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‑TKIs) are being increasingly used to treat lung cancer.; however, due to small sample sizes and a limited number of adequately controlled studies, it is difficult to compare survival rates of traditional chemotherapy with EGFR‑TKI therapy when used as a first‑ or second‑line treatment for patients with lung cancer, and therefore data on its efficacy are inconclusive. Therefore, Taiwan's entire 2010‑2015 National Health Insurance Database (NHID) was used to perform a retrospective study. The top two anti‑neoplastic first‑line therapies used for lung cancer were traditional platinum‑based doublet chemotherapy and EGFR‑TKI therapy. Patients with stage III and IV lung cancer undergoing first‑line EGFR‑TKI therapy exhibited improved overall survival rates. However, patients with stage I and II lung cancer demonstrated limited benefits. Patients with stage IIIB and IV EGFR mutation (‑) patients did not benefit from treatment with EGFR‑TKI therapy. The EGFR‑TKI gefitinib may be more effective in patients with lung cancer than erlotinib, irrespective of whether patients had been previously treated or not. Patients treated with Gefitinib also exhibited improved survival rates compared with other frequently used chemotherapeutic drugs.

View Figures

View References

1	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Wang BY, Huang JY, Cheng CY, Lin CH, Ko J and Liaw YP: Lung cancer and prognosis in Taiwan: A population-based cancer registry. J Thorac Oncol. 8:1128–1135. 2013. View Article : Google Scholar : PubMed/NCBI
4	Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol. 7:719–727. 2006. View Article : Google Scholar : PubMed/NCBI
5	Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, et al: Preoperative chemotherapy in patients with resectable non-small cell lung cancer: Results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 369:1929–1937. 2007. View Article : Google Scholar : PubMed/NCBI
6	Lim E, Harris G, Patel A, Adachi I, Edmonds L and Song F: Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: Systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 4:1380–1388. 2009. View Article : Google Scholar : PubMed/NCBI
7	NSCLC Meta-Analyses Collaborative Group, : Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 26:4617–4625. 2008. View Article : Google Scholar : PubMed/NCBI
8	Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T and Pignon JP: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA. 292:470–484. 2004. View Article : Google Scholar : PubMed/NCBI
9	Li M, Zhang Q, Fu P, Li P, Peng A, Zhang G, Song X, Tan M, Li X, Liu Y, et al: Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. PLoS One. 7:e372292012. View Article : Google Scholar : PubMed/NCBI
10	Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 91:66–72. 1999. View Article : Google Scholar : PubMed/NCBI
11	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
12	Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, et al: First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
13	Carter BW, Lichtenberger JP III, Benveniste MK, de Groot PM, Wu CC, Erasmus JJ and Truong MT: Revisions to the TNM staging of lung cancer: Rationale, significance, and clinical application. Radiographics. 38:374–391. 2018. View Article : Google Scholar : PubMed/NCBI
14	http://regulation.cde.org.tw/data/downloadfile.php?sid=910
15	Skrbo A, Begovic B and Skrbo S: Classification of drugs using the ATC system (Anatomic, Therapeutic, Chemical Classification) and the latest changes. Med Arh. 58 (1 Suppl 2):S138–S141. 2004.(In Bosnian).
16	Liang YH, Shao YY, Liao BC, Lee HS, Yang JC, Chen HM, Chiang CJ, Cheng AL and Lai MS: Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice. J Cancer. 7:1515–1523. 2016. View Article : Google Scholar : PubMed/NCBI
17	Masters GA, Temin S, Azzoli CG, et al: Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 33:3488–3515. 2015. View Article : Google Scholar : PubMed/NCBI
18	D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T and Shepherd FA: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature. J Clin Oncol. 23:2926–2936. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K and Ahn MJ: Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer. 75:82–88. 2012. View Article : Google Scholar : PubMed/NCBI
20	Chang CH, Lee CH, Ko JC, Chang LY, Lee MC, Wang JY and Yu CJ: Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: A cohort study in Taiwan. Cancer Med. 6:1563–1572. 2017. View Article : Google Scholar : PubMed/NCBI
21	Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet. 372:1809–1818. 2008. View Article : Google Scholar : PubMed/NCBI
22	Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B and Gonzalez EE: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. Lancet Oncol. 13:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
23	Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, et al: Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised controlled trial. Lancet Oncol. 14:981–988. 2013. View Article : Google Scholar : PubMed/NCBI